Expression of IAP family proteins in myelodysplastic syndromes transforming to overt leukemia

Leukemia Research
Kouhei YamamotoMasanobu Kitagawa

Abstract

Bone marrow cells of patients with myelodysplastic syndromes (MDS) frequently undergo apoptosis, though the apoptotic cell ratio decreases when overt leukemia (OL) develops. Thus, we compared the expression of the inhibitor of apoptosis protein (IAP) gene family proteins in bone marrow samples from control, MDS, OL transformed from MDS (MDS --> OL), and de novo acute myelogenous leukemia (AML) subjects by the quantitative real-time RT-PCR method and an immunohistochemical approach. Overexpression of mRNA for survivin, cIAP1, NAIP and XIAP was significant in MDS bone marrow cells compared with control samples. However, the expression of mRNA for survivin, cIAP1 and cIAP2 exhibited a remarkable decrease after the development of OL (MDS --> OL). By immunohistochemistry, survivin was found to localize to the nucleus of myeloid cells in the majority of MDS cases. Next, the chronological changes in the expression of IAPs were determined in cases of MDS with evolution of OL. Although the expression of cIAP1 and cIAP2 revealed a sudden or gradual decrease as OL developed, survivin in many cases and XIAP in the majority of cases exhibited a peak of expression before a decline, indicating that these IAPs could be associated with the earl...Continue Reading

References

Jan 1, 1989·Virchows Archiv. B, Cell Pathology Including Molecular Pathology·M KitagawaT Kasuga
Aug 1, 1997·Nature Medicine·G AmbrosiniD C Altieri
Nov 25, 1998·Seminars in Immunology·L A Vogel, R J Noelle
Jan 23, 1999·Oncogene·E C LaCasseA E MacKenzie
Dec 2, 1999·Nature Genetics·V E VelculescuK W Kinzler
Nov 25, 2000·British Journal of Haematology·C AdidaH Dombret
Nov 21, 2001·The Journal of Biological Chemistry·William H HoffmanMaureen Murphy
Apr 2, 2002·Experimental Cell Research·Jose A RodríguezGiuseppe Giaccone

❮ Previous
Next ❯

Citations

Dec 4, 2004·Cancer Immunology, Immunotherapy : CII·Masanobu KitagawaKatsuiku Hirokawa
Nov 25, 2006·Annals of Hematology·Umberto GianelliSilvano Bosari
Feb 28, 2006·Apoptosis : an International Journal on Programmed Cell Death·K L SilvaR C Maia
Oct 22, 2008·Oncogene·E C LaCasseR G Korneluk
Feb 25, 2006·Cell Death and Differentiation·T BraunG Kroemer
Aug 8, 2006·Oncogene·M FontenayE Solary
Aug 3, 2006·Journal of the National Cancer Institute·Boglarka GyurkoczaDario C Altieri
Mar 15, 2006·European Journal of Haematology·Rosangela InvernizziEdoardo Ascari
Mar 31, 2012·Laboratory Hematology : Official Publication of the International Society for Laboratory Hematology·Azza Mostafa IbrahimHanan Mohamed Al Wakeel
Apr 24, 2013·Targeted Oncology·Robert M SutphinRiyaz Basha
Apr 17, 2013·Expert Opinion on Investigational Drugs·Lakshmikanth KatragaddaGautam Borthakur
Mar 20, 2012·Journal of Bioscience and Bioengineering·Tomohisa HoribeKoji Kawakami
Jan 5, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Olga Grzybowska-IzydorczykPiotr Smolewski
Jul 9, 2008·Leukemia Research·Mohamad M Al-RahawanM Tarek Elghetany
Nov 3, 2007·Experimental Hematology·Daniella B Kerbauy, H Joachim Deeg
Aug 19, 2007·Leukemia Research·Yataro Yoshida
Apr 6, 2007·British Journal of Haematology·Tamara KeithMasanobu Kitagawa
Nov 17, 2011·European Journal of Haematology·Eman Abdel Rahman IsmailMahmoud Ahmed Abdelwahab
Jun 6, 2012·Hematology·Shigeaki UmedaMasanobu Kitagawa
Jul 16, 2008·Expert Opinion on Therapeutic Targets·S M C LangemeijerJ H Jansen
Dec 28, 2010·Molecular Cell·Jason B GarrisonJohn C Reed
Feb 24, 2005·American Journal of Hematology·Yasunori NakagawaMasanobu Kitagawa
Jan 12, 2019·Current Opinion in Hematology·Namrata S ChandhokThomas Prebet
Mar 6, 2019·British Journal of Haematology·Prajwal BodduNaveen Pemmaraju
Mar 5, 2019·International Journal of Cancer. Journal International Du Cancer·Laura K HillertInna N Lavrik
Nov 25, 2006·The Journal of Biological Chemistry·Pierre-Olivier EstèveSriharsa Pradhan
Dec 3, 2017·Journal of Neuro-oncology·Eric GoetheNaveen Pemmaraju

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.